key: cord-0978853-00zjgybv
authors: Chavda, Vivek P.; Patel, Aayushi B.; Vaghasiya, Darsh D.
title: SARS‐CoV‐2 variants and vulnerability at the global level
date: 2022-04-05
journal: J Med Virol
DOI: 10.1002/jmv.27717
sha: 52ac0dad5a00c10fe61634cd9507e1d53b781dd3
doc_id: 978853
cord_uid: 00zjgybv

Numerous variants of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) pandemic have evolved. As viral variants may evolve with harmful susceptibility to the immunity established with the existing COVID‐19 vaccination, these variations are more transmissible, induce relatively extreme illness, have evasive immunological features, decrease neutralization using antibodies from vaccinated persons, and are more susceptible to re‐infection. The Centers for Disease Control and Prevention (CDC) has categorized SARS‐CoV‐2 mutations as variants of interest (VOI), variants of concern (VOC), and variants of high consequence (VOHC). At the moment, four VOC and many variants of interest have been defined and require constant observation. This review article summarizes various variants of SARS‐CoV‐2 surfaced with special emphasis on VOCs that are spreading across the world, as well as several viral mutational impacts and how these modifications alter the properties of the virus.

| 1 domain (NTD), may also affect neutralizing antibody capacity. 16 A reconstituted SARS-CoV-2 (virus or genetic mutant) may have additional mutations that separate it from the basic pattern or common viral variants widely circulated in humans. 17 The proliferation of mutations poses a significant barrier for vaccination-based protection and management of the SARS-CoV-2 outbreak. Existing SARS-CoV-2 vaccines have been approved for immediate application. Those vaccines that are in clinical trials have also demonstrated substantial benefits in terms of offering effective coverage toward novel viral variants. 18 This review encompasses the impact of identified variants on neutralizing antibodies and the preventive effect of various vaccines. We have also proposed ways for using present vaccines toward variants as well as generating upcoming vaccines.

SARS-CoV-2 variants can have a variety of features. Testing results may be affected if a patient sample contains SARS-CoV-2 viral mutations. 19 Multiple factors, including the variant sequence, examination system, and the incidence of change in the population, are used to analyze the influence of mutations on test performance. 20 Typically, transcription or translation error in the viral genome is the main reason for mutation. 21 It has been shown that RNA viruses undergo mutation at higher rates than DNA viruses with mutation rates from 10 −6 to 10 −4 substitutions per nucleotide, per round of copying. 22 The high rate of mutation is correlated with an increase in evolvability and enhanced virulence, which is a beneficial survival trait for viruses. Mutation in viruses causes both geno-and phenotypic changes as seen in an influenza A virus. The main reason for mutation in the influenza A virus is the re-assortment of viral genomes from different strains. 23 The mutation causes the change in patterns of influenza A subtype H3N2 which is responsible for antigenic evolution in humans. 24 Influenza viruses are ever-shifting in two ways, antigenic drift and antigenic shift. The first is responsible for causing small mutation in genes of the virus which leads to changes in HA (hemagglutinin) and NA (neuraminidase), which are surface proteins and later creates a substantial shift in influenza A viral surface protein produces new HA and/or NA surface proteins, that are relevant to human infection. 25 In conjunction with the SARS-CoV-2 interagency committee, the CDC defined three categories of SARS-CoV-2 variants: variants of interest (VOI), variants of concern VOC, and variants of high consequence (VOHC). These variants are continually evolving as a result of the number of additional alterations (Figure 1 ). 26 

It is a variation associated with altered receptor binding, reduced neutralization by antibodies generated in response to past infection or immunization, reduced therapeutic efficacy, possible diagnostic effect, or an anticipated rise in infectivity or growth of the disease. This variation has a nonidentical sequence of receptor binding. 27 Antibodies that are created against additional infection or vaccination can reduce the neutralization. The efficacy of treatment gets reduces which leads to the possible impact of diagnosis or an anticipated increase in infectiousness, or intensity of the disease. 28 Table 1 summarizes VOI that are being monitored to date.

A mutation, known as D614G, is responsible for one specific viral activity. It is reflected in the reality that viruses with this F I G U R E 1 Variants of SARS-CoV-2 and their clade. (SARS-CoV-2, severe acute respiratory syndrome coronavirus 2).

alteration have a higher transmission rate than viruses without this variation. 32 In the starting phase of the pandemic, this mutation was one of the first documented mutation in the United States, after having initially circulated in Europe. 33 "The phylogenetic assignment of named global outbreak lineage (PANGOLIN)," also known as Pango lineage terminology, was used to designate SARS-CoV-2 variants. 34 The phylogeny of SARS-CoV-2 is divided into two primary lineages, A and B, as per nomenclature. The most typical lineage of variations is debated. 35 

A variation characterized by increased amplitude, a substantial decrease in treatment potency or vaccine performance due to neutralization with antibodies produced following previous sickness or inoculation, or diagnostic identification errors ( Figure 2 ). 36 The transmission rate is excessive in this variant type of SARS-CoV-2 (Tables 2 and 3) . A high rate of transmission leads to more acute disease. 42 There is a possible decrease in neutralization by antibodies produced from earlier illness or immunization. 43 The efficacy of medicines or vaccinations is decreased, or diagnostic recognition fails. 44 Table 4 47 In the United Kingdom, the very first case of the SARS-Cov-2 Alpha variant was detected in September 2020.

Furthermore, the Alpha variant is related to a greater death rate in patients in comparison with other variants. 48 The alteration in the S protein of the virus is the main reason behind its mutation. This new variant also carries NTD and RBD mutations, which play a vital part in the binding of a virus with host cells via the angiotensin-converting enzyme 2 (ACE2) receptor. S1 subunit of viral spike protein, which is made up of the NTD and the RBD, is essential for defining tissue tropism and host ranges. 49 The N501Y mutation in the RBD of the spike protein, and a few additional mutations, identify the Alpha variant. 50 Among these, there are two deletion mutations in the NTD of the S protein, HV69-70del and Y144del (also known as Y145del due to the presence of tyrosine at both positions). 51 55 The first incidence of the SARS-Cov-2 beta strain was identified in the United Kingdom in May 2020, and it was mostly discovered in South Africa. 56 The mutation caused an increase in transmissibility and also the neutralizing capacity of the virus. 26 There are three mutations of significant importance in the spike area of the lineage, B.1.351 genome, K417N, E484K, N501Y, and a further five spike mutations, L18F, D80A, D215G, R246I, A701V, that have so far raised little concern. Aside from the spike area, it also has K1655N, a deletion of SGF 3675-3677, P71L, and T205I. 57 T A B L E 1 VOI of SARS-CoV-2 as per the World Health Organization (WHO) pose even in situations where big epidemics have occurred. 69 Although the clinical significance and transmissibility of reinfections were not investigated, the projected reinfection rates imply that the gamma variation may cause a greater infection risk than earlier nongamma versions. As the majority of blood donors had asymptomatic or oligosymptomatic illnesses, the found protection against reinfection does not generalize to cohorts of exclusively hospitalized or symptomatic people. 64 were initially identified in California (USA). In the beginning, they were designated as CA VUI1 but afterward WHO classified them and labeled them "epsilon" on May 31, 2021. These variants have a 20%

higher efficiency than the original virus and can rapidly transmit from one individual to another. 71 The researchers studied the neutralizing incidence of the epsilon variants on antibodies present in the specimens using plasma from a COVID-19 recovered individual, along with an entirely immunized person and concluded that their potency was reduced. 72 An estimated rise in the transmission rate is high and it is found in multiple other states of the United States. 73 It has L452R mutation in S protein which was discovered in the RBD.

It increases infectivity because of the interaction between spike protein and ACE2 receptors. 75 W152C has been shown to diminish sensitivity to numerous NTD-binding monoclonal antibodies, implying yet another involvement in immune evasion. 76 95 Omicron has a mutation known as N501Y, which allows the virus to attach to human cells more firmly. This mutation was found in the Alpha variant as well, and it was connected to its infectivity. According to computational modeling, the variant may also be immune to cell-mediated immune function. 96 Furthermore, if some of the VOC have a higher risk of transmission or pathogenicity, the significance of effective public health interventions and immunization programs will grow. 72, 123 The international reaction must be both prompt and scientific. 140 We, humans, are racing against time to develop immunity to this elusive virus, whose ability to mutate and evolve seems to be outpacing our ability to achieve herd immunity. Due to the new variants, it may be a sprint to the finish line. 141 We, humans, are racing against time to develop immunity to this elusive virus, whose ability to mutate and evolve seems to be outpacing our ability to achieve herd immunity. Due to the new variants, it may be a sprint to the finish line. 142 These variants are concerning for several reasons. First, the SARS-CoV-2 VOC spread at least 20%−50% more quickly from person to person. This encourages them to infect more people and grow faster and farther, gradually becoming the dominant paradigm. Second, SARS-CoV-2 VOC can create more acute illness, as well as an uptick in hospitalizations and deaths. In other words, they may be more virulent. 143 According to Richard Lessells, "If a virus is going through an evolutionary process inside the host, then it is quite likely that it would be adapting to be better at entering the cells and evading the immune response; this could lead to a variant with enhanced transmissibility and enhanced immune evasion."

Herbal remedies, 144 drug repurposing, and nanotechnologybased formulations are also proved to be efficient in disease management. [140] [141] [142] [143] [144] [145] [146] [147] We can see the consequences: tragic deaths, worldwide epidemic outbreaks, and lockdowns. 148 

The authors declare no conflicts of interest.

Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.

Vivek P. Chavda http://orcid.org/0000-0002-7701-8597

Omicron variant (B.1.1.529) of SARS-CoV-2: threat for the elderly?

Therapeutics for COVID-19 and post COVID-19 complications: an update

Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies

Sequence analysis of SARS-CoV-2 genome reveals features important for vaccine design

Mechanisms of viral mutation

The nonstructural proteins directing coronavirus RNA synthesis and processing

A global picture: therapeutic perspectives for COVID-19

Darunavir ethanolate: repurposing an anti-HIV drug in COVID-19 treatment

Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees

Increased elastase sensitivity and decreased intramolecular interactions in the more transmissible 501Y.V1 and 501Y.V2 SARS-CoV-2 variants' spike protein-an in silico analysis

DNA vaccines for SARS-CoV-2: towards third generation vaccination era

Mucormycosis-an opportunistic infection in the aged immunocompromised individual: a reason for concern in COVID-19

Intranasal vaccines for SARS-CoV-2: from challenges to potential in COVID-19 management

Nucleic acid vaccines for COVID-19: a paradigm shift in the vaccine development arena

COVAX-19 ® vaccine: completely blocks virus transmission to non-immune individuals

Emerging SARS-CoV-2 variants: a review of its mutations, its implications and vaccine efficacy

Emerging SARS-CoV-2 variants of concern and potential intervention approaches

What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2

SARS-CoV-2 E gene variant alters analytical sensitivity characteristics of viral detection using a commercial reverse transcription-PCR assay

Laboratory diagnosis of COVID-19: current issues and challenges

Transcriptional mutagenesis: causes and involvement in tumour development

New viral vaccines

Gut microbiota status in COVID-19: an unrecognized player?

The effects of a deleterious mutation load on patterns of influenza A/H3N2' s antigenic evolution in humans

Drift" and "Shift". Centers for Disease Control and Prevention, National Center for Immunization and Respiratory Diseases (NCIRD)

Division of Viral Diseases

SARS-CoV-2 variants of interest and concern naming scheme conducive for global discourse

The COVID-19 vaccine landscape

The emergence of Sars-CoV-2 variant Lambda (C.37) in South America

Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study

A novel SARS-CoV-2 variant of concern, B.1.526, identified in New York. medRxiv Prepr Serv Heal Sci

mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants

Recurrent emergence of SARS-CoV-2 spike deletion H69/V70 and its role in the Alpha variant B.1.1.7. Cell Rep

Pango lineage designation and assignment using SARS-CoV-2 spike gene nucleotide sequences

Transmission, infectivity, and antibody neutralization of an emerging SARS-CoV-2 variant in California carrying a L452R spike protein mutation. medRxiv Prepr Serv Heal Sci

SARS-CoV-2 variants of concern

A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology

Transmission dynamics and mutational prevalence of the novel severe acute respiratory syndrome coronavirus-2 Omicron Variant of Concern

SARS-CoV-2 spike E484K mutation reduces antibody neutralisation. The Lancet Microbe

Global impact of delta plus variant and vaccination

Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies

Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19). StatPearls [Internet

The origin of SARS-CoV-2 variants of concern

Division of Viral Diseases

Alpha variant SARS-CoV-2 infection: how it all starts

Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study

The SARS-CoV-2 B. 1. 351 lineage (VOC β) is outgrowing the B 1. 1. 7 lineage (VOC α) in some French regions in

Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7

Generation time of the alpha and delta SARS-CoV-2 variants: an epidemiological analysis

Effect of Covid-19 vaccination on transmission of alpha and delta variants

Gamma: what's important to know about SARS-CoV-2 variants of concern?

Rapidly emerging SARS-CoV-2 B.1.1.7 sub-lineage in the United States of America with spike protein D178H and membrane protein V70L mutations

Tracking the emergence of SARS-CoV-2 alpha variant in the United Kingdom

SARS-CoV-2 variants of concern: the knowns and unknowns

Exploring the COVID-19 vaccine candidates against SARS-CoV-2 and its variants: where do we stand and where do we go?

Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera

Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST Guideline and Expert Panel Report

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

Isolation and characterization of SARS-CoV-2 Beta variant from UAE travelers

Antibody evasion by the P.1 strain of SARS-CoV-2

World Health Organization. COVID-19 weekly epidemiological update 22

Factor influences for diagnosis and vaccination of avian infectious bronchitis virus (Gammacoronavirus) in chickens

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): an update

SARS-CoV-2 variant of concern P.1 (Gamma) infection in young and middle-aged patients admitted to the intensive care units of a single hospital in Salvador, Northeast Brazil

SARS-CoV-2: from its discovery to genome structure, transcription, and replication

Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2

Introduction of Brazilian SARS-CoV-2 484K.V2 related variants into the UK

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Reinfection by the SARS-CoV-2 Gamma variant in blood donors in Manaus, Brazil

SARS-CoV-2 Lambda and Gamma variants competition in Peru, a country with high seroprevalence

Identification of and surveillance for the SARS-CoV-2 variants B.1.427 and B.1.429-Colorado

The origins and potential future of SARS-CoV-2 variants of concern in the evolving COVID-19 pandemic

Emergence of SARS-CoV-2 Omicron (B.1.1.529) variant, salient features, high global health concerns and strategies to counter it amid ongoing COVID-19 pandemic

Analysis of delayed vaccination regimens: a mathematical modeling approach

Covid-19: India is at centre of global vaccine manufacturing, but opacity threatens public trust

SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern

Variants of SARS-CoV-2

SARS-CoV-2 variants and their relevant mutational profiles: update summer 2021

SARS-CoV-2 variants, spike mutations and immune escape

Genetic variants of SARS-CoV-2-what do they mean?

Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in Maharashtra

Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study

Present variants of concern and variants of interest of severe acute respiratory syndrome coronavirus 2: their significant mutations in S-glycoprotein, infectivity, re-infectivity, immune escape and vaccines activity

Effectiveness of COVID-19 vaccines against the B. 1. 617. 2 variant

Infection and vaccine-induced neutralizing antibody responses to the SARS-CoV-2 B.1.617.1 variant

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants

Covid-19: single vaccine dose is 33% effective against variant from India, data show

An overview of basic molecular biology of SARS-CoV-2 and current COVID-19 prevention strategies

Waves and variants of SARS-CoV-2: understanding the causes and effect of the COVID-19 catastrophe

Evolutionary analysis of the Delta and Delta Plus variants of the SARS-CoV-2 viruses

Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Severe asthma in the era of COVID-19: a narrative review

COVID-19: what do we know about the C.1.2 variant. Medical News Today

Classification of Omicron (B.1.1.529): SARS-CoV-2 variant of concern

Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529)-highlights Africa's research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts

Heavily mutated Omicron variant puts scientists on alert

SARS-CoV-2 Variants of Concern and Variants under Investigation in England

An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment

The spike of concern -the novel variants of SARS-CoV-2

Counting on COVID-19 vaccine: insights into the current strategies, progress and future challenges

COVID-19 pandemics Stage II-energy and environmental impacts of vaccination

Post-recovery enhancement of anti-variant neutralisation after severe COVID-19. The Lancet Microbe

Omicron adopts a different strategy from Delta and other variants to adapt to host

SARS-CoV-2 Omicron variant is highly sensitive to molnupiravir, nirmatrelvir, and the combination

Comment global emergence of SARS-CoV-2 variants: new foresight needed for improved vaccine efficacy

Analysis of vaccine effectiveness against COVID-19 and the emergence of delta and other variants of concern in Utah

The COVID-19 vaccine development landscape

COVID-19: breaking down a global health crisis

Lessons learned 1 year after SARS-CoV-2 emergence leading to COVID-19 pandemic

A machine-generated view of the role of blood glucose levels in the severity of COVID-19

Haplotype distribution of SARS-CoV-2 variants in low and high vaccination rate countries during ongoing global COVID-19 pandemic in early 2021

Tools and techniques for severe acute respiratory syndrome coronavirus

COVID-19 detection

Global vaccine action plan

COVID-19: current knowledge in clinical features, immunological responses, and vaccine development

Looking beyond COVID-19 vaccine phase 3 trials

COVID-19 Vaccine Tracker and Landscape

Special Report SARS-CoV-2 variants and vaccines

Progress and pitfalls in the quest for effective SARS-CoV-2 (COVID-19) vaccines. Front Immunol

SARS-CoV-2 Vaccines and the growing threat of viral variants

COVID-19: insights into potential vaccines. Microorganisms

Omicron variant (B.1.1.529) of SARS-CoV-2: mutation, infectivity, transmission, and vaccine resistance

The COVID-19 pandemic: viral variants and vaccine efficacy

Booster vaccination to reduce SARS-CoV-2 transmission and infection

Sorting out whether vitamin D deficiency raises COVID-19 risk

Is booster dose strategy sufficient for Omicron variant of SARS-CoV-2? Vaccines

Low COVID-19 vaccine acceptance is correlated with conspiracy beliefs among university students in Jordan

Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel

Effectiveness of BNT162b2 vaccine against Omicron variant in South Africa

DNA vaccines for SARS-CoV-2: toward third-generation vaccination era

Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants

Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine

Dominance of Alpha and Iota variants in SARS-CoV-2 vaccine breakthrough infections in New York City

Mini-review discussing the reliability and efficiency of COVID-19 vaccines

An updated review on potential therapeutic drug candidates, vaccines and an insight on patents filed for COVID-19

CoronaVac induces lower neutralising activity against variants of concern than natural infection

COVAXIN ® -India' s First Indigenous COVID-19 Vaccine

Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: present and future

Asian-origin approved COVID-19 vaccines and current status of COVID-19 vaccination program in Asia: a critical analysis

Global access to COVID-19 vaccines: a scoping review of factors that may influence equitable access for low and middle-income countries

How worried should you be about coronavirus variants? A virologist explains his concerns. DownToEarth

Rethinking the central role of equity in the global governance of pandemic response

Herbal remedies, nutraceuticals, and dietary supplements for COVID-19 management: an update

New bioinformatics platform-based approach for drug design

Phytochemical delivery through Transferosome (Phytosome): an advanced transdermal drug delivery for complementary medicine

Applications of Targeted Nano Drugs and Delivery Systems

In the shadow of biological warfare: conspiracy theories on the origins of COVID-19 and enhancing global governance of biosafety as a matter of urgency

Emergency Use Authorization (EUA) for etesevimab

Casirivimab with imdevimab-USFDA Factsheet. fda.gov. 2021

New strategies in drug discovery

Advanced computational methodologies used in the discovery of new natural anticancer compounds

Chapter 4-nanobased nano drug delivery: a comprehensive review

Medication conveyance framework: an approach for brain delivery from essential to cutting edge

Phytochemical delivery through transferosome (phytosome): an advanced transdermal drug delivery for complementary medicines

How to cite this article: Chavda VP

SARS-CoV-2 variants and vulnerability at the global level